Evidence map›Paper›PMID 27777593›Full record

ReviewAllergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology2016

Genetic and epigenetic studies of atopic dermatitis.

Lianghua Bin, Donald Y M Leung

Registry-linked trialOpen access · goldAbstract readReview
In one paragraph

Review in Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05719649 (The Efficacy of NTU 101 Lactic Acid Bacteria Powder in the Adjuvant Improvement of Atopic Dermatitis - A Double-blind, Multi-center Randomized, Placebo-controlled Clinical Trial), which is not on this map. Cited by 105 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
105citing papers in PubMed, 3 pooled it
24.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05719649 naunknown statusnot on this mapstarted 2023, after this paper: background citation

The Efficacy of NTU 101 Lactic Acid Bacteria Powder in the Adjuvant Improvement of Atopic Dermatitis - A Double-blind, Multi-center Randomized, Placebo-controlled Clinical Trial

TypeinterventionalSponsorSunWay Biotech Co., LTD.Ran2023 to 2023Enrolled72ConditionsAtopic Dermatitis, Atopic Dermatitis EczemaArmsLactic acid bacteria NTU 101, Placebo
3 · Its place in the literature

Who cites it

105 citing papers in PubMed, 3 syntheses or guidelines pooled it, 241 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Therapeutic responses toScience translational medicine · 2020
    Trial
  6. Trial
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Type 2 Inflammation and Its Role in Dermatologic Diseases.International journal of dermatology · 2025
    Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. TThe Journal of allergy and clinical immunology · 2024
    Review

45 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Lianghua BinThe Department of Dermatology, the First Affiliated Hospital, Jinan University, Guangzhou, China ; Biomedical Translational Research Institute, Jinan University, Guangzhou, China ; Department of Pediatrics, National Jewish Health, 1400 Jackson Street, Room K926i, Denver, CO 80206 USA.ORCID 0000-0002-3786-0106
Donald Y M LeungDepartment of Pediatrics, National Jewish Health, 1400 Jackson Street, Room K926i, Denver, CO 80206 USA ; Guangdong Provincial Key Laboratory of Allergy & Clinical Immunology, The State Key Clinical Specialty in Allergy, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
First Affiliated Hospital of Jinan University · CNNational Jewish Health · US

Funding

Targeted Microbiome Transplant in Atopic DermatitisU19AI117673 · NIAID · NATIONAL JEWISH HEALTH · PI LEUNG, DONALD YM · 2015 to 2019
$30.6M
SEAL (Stopping Atopic dermatitis and ALlergy) Study: Prevent allergy by enhancing the skin barrierU01AI147462 · NIAID · STANFORD UNIVERSITY · PI Mary Johnson, GIDEON LACK · 2020 to 2026
$14.0M
THE ROLE OF BACTERIAL TOXINS IN HUMAN SKIN DISEASER01AR041256 · NIAMS · NATIONAL JEWISH HEALTH · PI GOLEVA, ELENA, LEUNG, DONALD YM · 1992 to 2020
$5.9M
NIAID NIH HHS HHSN272201000020CNIAID NIH HHS HHSN272201000020INIAID NIH HHS U01 AI147462NIAID NIH HHS U19 AI117673NIAMS NIH HHS R01 AR041256
6 · The paper itself

Abstract

backgroundAtopic dermatitis (AD) is a chronic inflammatory disease caused by the complex interaction of genetic, immune and environmental factors. There have many recent discoveries involving the genetic and epigenetic studies of AD.

methodsA retrospective PubMed search was carried out from June 2009 to June 2016 using the terms "atopic dermatitis", "association", "eczema", "gene", "polymorphism", "mutation", "variant", "genome wide association study", "microarray" "gene profiling", "RNA sequencing", "epigenetics" and "microRNA". A total of 132 publications in English were identified.

resultsTo elucidate the genetic factors for AD pathogenesis, candidate gene association studies, genome-wide association studies (GWAS) and transcriptomic profiling assays have been performed in this period. Epigenetic mechanisms for AD development, including genomic DNA modification and microRNA posttranscriptional regulation, have been explored. To date, candidate gene association studies indicate that filaggrin (

conclusionsThe results suggest that two major biologic pathways are responsible for AD etiology: skin epithelial function and innate/adaptive immune responses. The dysfunctional epidermal barrier and immune responses reciprocally affect each other, and thereby drive development of AD.

Indexed as

Adaptive immunityAtopic dermatitisDNA methylationEpigeneticGenetic associationGeneticsInnate immunitymiRNASkin barrier

Identifiers

PMID27777593
PMCPMC5069938
OpenAlexW2537143772

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.